English Polski
Vol 33, No 61 (2023)
Review paper
Published online: 2024-02-23

open access

Page views 88
Article views/downloads 53
Get Citation

Connect on Social Media

Connect on Social Media

miRNAs as potential biomarkers for childhood epilepsy

Beata Rzepka-Migut1, Justyna Paprocka2
DOI: 10.5603/cn.99009
Neurol Dziec 2023;33(61):20-29.


Introduction: Epilepsy is one of the most common and devastating neurological diseases in pediatric patients This has led researchers to search for the molecular basis of the disease and to try to find a targeted treatment, which is an extremely difficult challenge due to the complexity of the etiopathogenesis of epilepsy. An alternative research option is focused on the search for biomarkers. miRNAs are small non-coding RNAs, 18-25 nucleotides long, which negatively regulate gene expression at the post-transcriptional level by inhibiting protein translation or mRNA degradation. The aim of the study was to analyze the available literature focusing on the evaluation of changes in the expression profile of selected miRNAs in children with epilepsy.
Materials and methods: The literature review was conducted in accordance with PRISMA Statement (Preferred Reporting Items for Systematic Reviews and Meta-analyses). The search covered the period from September 1, 2010 to December 1, 2022.

Results: 17 publications were included in the analysis. A growing trend of interest in the topic of miRNA use in epilepsy is evident, with most papers published in the last 5 years. Twenty-six different miRNAs were analyzed by PCR. The authors summarized articles assessing different miRNAs as potential diagnostic and prognostic biomarkers of epilepsy using a ROC curve.

Conclusions: The number of studies investigating miRNAs as potential prognostic and diagnostic biomarkers for epilepsy is growing rapidly. However, the results of these studies need to be verified in independent cohorts also including children with epilepsy.

Article available in PDF format

View PDF (Polish) Download PDF file


  1. Nickels KC, Wong-Kisiel LC, Moseley BD, et al. Temporal lobe epilepsy in children. Epilepsy Res Treat. 2012; 2012: 849540.
  2. Tyburski J, Studzinska A, Daca P, et al. PCR w czasie rzeczywistym. Metody analizy danych Biotechnologia. 2008; 1: 86–96.
  3. Chen M, Zhao QY, Edson J, et al. Genome-wide microRNA profiling in brain and blood samples in a mouse model of epileptogenesis. Epilepsy Res. 2020; 166: 106400.
  4. Brennan GP, Henshall DC. MicroRNAs as regulators of brain function and targets for treatment of epilepsy. Nat Rev Neurol. 2020; 16(9): 506–519.
  5. Baloun J, Bencurova P, Totkova T, et al. Epilepsy miRNA Profile Depends on the Age of Onset in Humans and Rats. Front Neurosci. 2020; 14: 924.
  6. Kumar P. miRNA dysregulation in traumatic brain injury and epilepsy: a systematic review to identify putative biomarkers for post-traumatic epilepsy. Metab Brain Dis. 2023; 38(3): 749–765.
  7. Brindley E, Hill TDM, Henshall DC. MicroRNAs as biomarkers and treatment targets in status epilepticus. Epilepsy Behav. 2019; 101(Pt B): 106272.
  8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700.
  9. Liu Ya, Yu G, Ding YY, et al. Expression of miR-155 in Serum Exosomes in Children with Epilepsy and Its Diagnostic Value. Dis Markers. 2022; 2022: 7979500.
  10. Wang Y, Wang Y, Chen Yi, et al. Circulating MicroRNAs From Plasma Small Extracellular Vesicles as Potential Diagnostic Biomarkers in Pediatric Epilepsy and Drug-Resistant Epilepsy. Front Mol Neurosci. 2022; 15: 823802.
  11. Li C, Zheng X, Liu P, et al. Clinical value of lncRNA TUG1 in temporal lobe epilepsy and its role in the proliferation of hippocampus neuron via sponging miR-199a-3p. Bioengineered. 2021; 12(2): 10666–10673.
  12. Wu Y, Zhang Y, Zhu S, et al. MiRNA-29a serves as a promising diagnostic biomarker in children with temporal lobe epilepsy and regulates seizure-induced cell death and inflammation in hippocampal neurons. Epileptic Disord. 2021; 23(6): 823–832.
  13. Niu X, Zhu HL, Liu Q, et al. MiR-194-5p serves as a potential biomarker and regulates the proliferation and apoptosis of hippocampus neuron in children with temporal lobe epilepsy. J Chin Med Assoc. 2021; 84(5): 510–516.
  14. Yu Y, Du L, Zhang J. Febrile Seizure-Related miR-148a-3p Exerts Neuroprotection by Promoting the Proliferation of Hippocampal Neurons in Children with Temporal Lobe Epilepsy. Dev Neurosci. 2021; 43(5): 312–320.
  15. Fu M, Tao J, Wang D, et al. Downregulation of MicroRNA-34c-5p facilitated neuroinflammation in drug-resistant epilepsy. Brain Res. 2020; 1749: 147130.
  16. Li Na, Pan J, Liu W, et al. MicroRNA-15a-5p serves as a potential biomarker and regulates the viability and apoptosis of hippocampus neuron in children with temporal lobe epilepsy. Diagn Pathol. 2020; 15(1): 46.
  17. Elnady HG, Abdelmoneam N, Eissa E, et al. MicroRNAs as Potential Biomarkers for Childhood Epilepsy. Open Access Maced J Med Sci. 2019; 7(23): 3965–3969.
  18. Wang Li, Song L, Chen X, et al. microRNA-139-5p confers sensitivity to antiepileptic drugs in refractory epilepsy by inhibition of MRP1. CNS Neurosci Ther. 2020; 26(4): 465–474.
  19. Wu X, Wang Y, Sun Z, et al. Molecular expression and functional analysis of genes in children with temporal lobe epilepsy. J Integr Neurosci. 2019; 18(1): 71–77.
  20. Ren L, Zhu R, Li X. Silencing miR-181a produces neuroprotection against hippocampus neuron cell apoptosis post-status epilepticus in a rat model and in children with temporal lobe epilepsy. Genet Mol Res. 2016; 15(1).
  21. Li L, Liu CQ, Li TF, et al. Analysis of Altered Micro RNA Expression Profiles in Focal Cortical Dysplasia IIB. J Child Neurol. 2016; 31(5): 613–620.
  22. Lee JiY, Park AK, Lee ES, et al. miRNA expression analysis in cortical dysplasia: regulation of mTOR and LIS1 pathway. Epilepsy Res. 2014; 108(3): 433–441.
  23. Ashhab MU, Omran A, Kong H, et al. Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy. J Mol Neurosci. 2013; 51(3): 950–958.
  24. Peng J, Omran A, Ashhab MU, et al. Expression patterns of miR-124, miR-134, miR-132, and miR-21 in an immature rat model and children with mesial temporal lobe epilepsy. J Mol Neurosci. 2013; 50(2): 291–297.
  25. Omran A, Peng J, Zhang C, et al. Interleukin-1β and microRNA-146a in an immature rat model and children with mesial temporal lobe epilepsy. Epilepsia. 2012; 53(7): 1215–1224.
  26. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342(5): 314–319.
  27. Bauer S, Schütz V, Strzelczyk A, et al. Is there a role for microRNAs in epilepsy diagnostics? Expert Rev Mol Diagn. 2020; 20(7): 693–701.
  28. Chen Xi, Ba Yi, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10): 997–1006.
  29. Hu K, Zhang C, Long L, et al. Expression profile of microRNAs in rat hippocampus following lithium-pilocarpine-induced status epilepticus. Neurosci Lett. 2011; 488(3): 252–257.
  30. Wang J, Yu JT, Tan L, et al. Genome-wide circulating microRNA expression profiling indicates biomarkers for epilepsy. Sci Rep. 2015; 5: 9522.
  31. Roncon P, Zucchini S, Ferracin M, et al. Is autopsy tissue a valid control for epilepsy surgery tissue in microRNA studies? Epilepsia Open. 2016; 2(1): 90–95.
  32. McKiernan RC, Jimenez-Mateos EM, Bray I, et al. Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis. PLoS One. 2012; 7(5): e35921.
  33. Sohel M. Extracellular/Circulating MicroRNAs: Release Mechanisms, Functions and Challenges. Achievements in the Life Sciences. 2016; 10(2): 175–186.
  34. Gallo A, Tandon M, Alevizos I, et al. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012; 7(3): e30679.
  35. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56(11): 1733–1741.
  36. Cogswell JP, Ward J, Taylor IA, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008; 14(1): 27–41.
  37. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30): 10513–10518.
  38. Raoof R, Jimenez-Mateos EM, Bauer S, et al. Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus. Sci Rep. 2017; 7(1): 3328.
  39. Raoof R, Bauer S, El Naggar H, et al. Dual-center, dual-platform microRNA profiling identifies potential plasma biomarkers of adult temporal lobe epilepsy. EBioMedicine. 2018; 38: 127–141.
  40. Brennan G, Bauer S, Engel T, et al. Genome-wide microRNA profiling of plasma from three different animal models identifies biomarkers of temporal lobe epilepsy. Neurobiol Dis. 2020; 144: 105048.
  41. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012; 149(3): 515–524.
  42. Schmiedel JM, Klemm SL, Zheng Y, et al. Gene expression. MicroRNA control of protein expression noise. Science. 2015; 348(6230): 128–132.
  43. Bartel DP. Metazoan MicroRNAs. Cell. 2018; 173(1): 20–51.
  44. Selbach M, Schwanhäusser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008; 455(7209): 58–63.
  45. Vinchure OS, Kulshreshtha R. miR-490: A potential biomarker and therapeutic target in cancer and other diseases. J Cell Physiol. 2021; 236(5): 3178–3193.
  46. Ludwig N, Leidinger P, Becker K, et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016; 44(8): 3865–3877.
  47. Martinez B, Peplow PV. MicroRNAs as potential biomarkers in temporal lobe epilepsy and mesial temporal lobe epilepsy. Neural Regen Res. 2023; 18(4): 716–726.
  48. McCall MN, Kim MS, Adil M, et al. Toward the human cellular microRNAome. Genome Res. 2017; 27(10): 1769–1781.
  49. Nowakowski TJ, Rani N, Golkaram M, et al. Regulation of cell-type-specific transcriptomes by microRNA networks during human brain development. Nat Neurosci. 2018; 21(12): 1784–1792.
  50. Kye MJ, Liu T, Levy SF, et al. Somatodendritic microRNAs identified by laser capture and multiplex RT-PCR. RNA. 2007; 13(8): 1224–1234.
  51. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005; 33(20): e179.
  52. Srivastava A, Dixit AB, Banerjee J, et al. Role of inflammation and its miRNA based regulation in epilepsy: Implications for therapy. Clin Chim Acta. 2016; 452: 1–9.
  53. Bielefeld P, Mooney C, Henshall DC, et al. miRNA-Mediated Regulation of Adult Hippocampal Neurogenesis; Implications for Epilepsy. Brain Plast. 2017; 3(1): 43–59.
  54. Ma Y. The Challenge of microRNA as a Biomarker of Epilepsy. Curr Neuropharmacol. 2018; 16(1): 37–42.
  55. Cattani AA, Allene C, Seifert V, et al. Involvement of microRNAs in epileptogenesis. Epilepsia. 2016; 57(7): 1015–1026.
  56. McClelland S, Flynn C, Dubé C, et al. Neuron-restrictive silencer factor-mediated hyperpolarization-activated cyclic nucleotide gated channelopathy in experimental temporal lobe epilepsy. Ann Neurol. 2011; 70(3): 454–464.
  57. Hu Y, Lund IV, Gravielle MC, et al. Surface expression of GABAA receptors is transcriptionally controlled by the interplay of cAMP-response element-binding protein and its binding partner inducible cAMP early repressor. J Biol Chem. 2008; 283(14): 9328–9340.
  58. Brennan GP, Dey D, Chen Y, et al. Dual and Opposing Roles of MicroRNA-124 in Epilepsy Are Mediated through Inflammatory and NRSF-Dependent Gene Networks. Cell Rep. 2016; 14(10): 2402–2412.
  59. McClelland S, Brennan GP, Dubé C, et al. The transcription factor NRSF contributes to epileptogenesis by selective repression of a subset of target genes. Elife. 2014; 3: e01267.
  60. Hauser RM, Henshall DC, Lubin FD. The Epigenetics of Epilepsy and Its Progression. Neuroscientist. 2018; 24(2): 186–200.
  61. Kobow K, Ziemann M, Kaipananickal H, et al. Genomic DNA methylation distinguishes subtypes of human focal cortical dysplasia. Epilepsia. 2019; 60(6): 1091–1103.
  62. Henshall DC, Hamer HM, Pasterkamp RJ, et al. MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol. 2016; 15(13): 1368–1376.
  63. Leontariti M, Avgeris M, Katsarou MS, et al. Circulating miR-146a and miR-134 in predicting drug-resistant epilepsy in patients with focal impaired awareness seizures. Epilepsia. 2020; 61(5): 959–970.
  64. Aronica E, Fluiter K, Iyer A, et al. Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. Eur J Neurosci. 2010; 31(6): 1100–1107.
  65. Omran A, Peng J, Zhang C, et al. Interleukin-1β and microRNA-146a in an immature rat model and children with mesial temporal lobe epilepsy. Epilepsia. 2012; 53(7): 1215–1224.
  66. An N, Zhao W, Liu Y, et al. Elevated serum miR-106b and miR-146a in patients with focal and generalized epilepsy. Epilepsy Res. 2016; 127: 311–316.
  67. Sheedy FJ, O'Neill LAJ. Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Ann Rheum Dis. 2008; 67 Suppl 3: iii50–iii55.
  68. Gaudet AD, Fonken LK, Watkins LR, et al. MicroRNAs: Roles in Regulating Neuroinflammation. Neuroscientist. 2018; 24(3): 221–245.
  69. Iori V, Iyer A, Ravizza T, et al. Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. Neurobiol Dis. 2017; 99: 12–23.
  70. Huang LG, Zou J, Lu QC. Silencing rno-miR-155-5p in rat temporal lobe epilepsy model reduces pathophysiological features and cell apoptosis by activating Sestrin-3. Brain Res. 2018; 1689: 109–122.
  71. Fu H, Cheng Y, Luo H, et al. Silencing MicroRNA-155 Attenuates Kainic Acid-Induced Seizure by Inhibiting Microglia Activation. Neuroimmunomodulation. 2019; 26(2): 67–76.
  72. Dogini DB, Avansini SH, Vieira AS, et al. MicroRNA regulation and dysregulation in epilepsy. Front Cell Neurosci. 2013; 7: 172.
  73. Henshall DC. MicroRNAs in the pathophysiology and treatment of status epilepticus. Front Mol Neurosci. 2013; 6: 37.
  74. McKiernan RC, Jimenez-Mateos EM, Sano T, et al. Expression profiling the microRNA response to epileptic preconditioning identifies miR-184 as a modulator of seizure-induced neuronal death. Exp Neurol. 2012; 237(2): 346–354.
  75. Geng H, Chen X. Development and validation of a nomogram for the early prediction of drug resistance in children with epilepsy. Front Pediatr. 2022; 10: 905177.
  76. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20(8): 460–469.
  77. Zampetaki A, Mayr M. Analytical challenges and technical limitations in assessing circulating miRNAs. Thromb Haemost. 2012; 108(4): 592–598.
  78. Sato F, Tsuchiya S, Terasawa K, et al. Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS One. 2009; 4(5): e5540.
  79. van Dijk EL, Jaszczyszyn Y, Thermes C. Library preparation methods for next-generation sequencing: tone down the bias. Exp Cell Res. 2014; 322(1): 12–20.
  80. Ruijter JM, Pfaffl MW, Zhao S, et al. Evaluation of qPCR curve analysis methods for reliable biomarker discovery: bias, resolution, precision, and implications. Methods. 2013; 59(1): 32–46.
  81. Bustin SA, Benes V, Garson J, et al. The need for transparency and good practices in the qPCR literature. Nat Methods. 2013; 10(11): 1063–1067.
  82. Bustin SA, Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech. 2004; 15(3): 155–166.

Child Neurology — Neurologia Dziecięca